Literature DB >> 26979081

Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy.

Abigail K Suwala1, Allison Hanaford1, Ulf D Kahlert1, Jaroslaw Maciaczyk2.   

Abstract

Glioblastoma (GBM) is the most malignant brain tumor and has a dismal prognosis. Aberrant WNT signaling is known to promote glioma cell growth and dissemination and resistance to conventional radio- and chemotherapy. Moreover, a population of cancer stem-like cells that promote glioma growth and recurrence are strongly dependent on WNT signaling. Here, we discuss the role and mechanisms of aberrant canonical and noncanonical WNT signaling in GBM. We present current clinical approaches aimed at modulating WNT activity and evaluate their clinical perspective as a novel treatment option for GBM.
© 2016 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Glioma; Inhibitors; Noncanonical WNT signaling; Prognostic markers; Small molecules; WNT

Mesh：

Substances：

Year:  2016        PMID： 26979081     DOI： 10.1093/jnen/nlw013

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN： 0022-3069            Impact factor:   3.685


  15 in total

1.  Glioblastoma cells vampirize WNT from neurons and trigger a JNK/MMP signaling loop that enhances glioblastoma progression and neurodegeneration.

Authors:  Marta Portela; Varun Venkataramani; Natasha Fahey-Lozano; Esther Seco; Maria Losada-Perez; Frank Winkler; Sergio Casas-Tintó
Journal:  PLoS Biol       Date:  2019-12-17       Impact factor: 8.029

2.  Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt.

Authors:  Ahmed El-Sehemy; Hayden Selvadurai; Arturo Ortin-Martinez; Neno Pokrajac; Yasin Mamatjan; Nobuhiko Tachibana; Katherine Rowland; Lilian Lee; Nicole Park; Kenneth Aldape; Peter Dirks; Valerie A Wallace
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 3.  Contribution of the Wnt Pathway to Defining Biology of Glioblastoma.

Authors:  Marton Tompa; Ferenc Kalovits; Adam Nagy; Bernadette Kalman
Journal:  Neuromolecular Med       Date:  2018-09-26       Impact factor: 3.843

4.  Wnt signalling is a bi-directional vulnerability of cancer cells.

Authors:  David J Duffy; Aleksandar Krstic; Thomas Schwarzl; Melinda Halasz; Kristiina Iljin; Dirk Fey; Bridget Haley; Jenny Whilde; Saija Haapa-Paananen; Vidal Fey; Matthias Fischer; Frank Westermann; Kai-Oliver Henrich; Steffen Bannert; Desmond G Higgins; Walter Kolch
Journal:  Oncotarget       Date:  2016-09-13

5.  Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ.

Authors:  Xia Qiu; Jianguo Jiao; Yidong Li; Tian Tian
Journal:  Oncotarget       Date:  2016-12-27

Review 6.  The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor.

Authors:  Mariachiara Zuccarini; Patricia Giuliani; Sihana Ziberi; Marzia Carluccio; Patrizia Di Iorio; Francesco Caciagli; Renata Ciccarelli
Journal:  Genes (Basel)       Date:  2018-02-17       Impact factor: 4.096

7.  Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro.

Authors:  Abigail Kora Suwala; Katharina Koch; Dayana Herrera Rios; Philippe Aretz; Constanze Uhlmann; Isabella Ogorek; Jörg Felsberg; Guido Reifenberger; Karl Köhrer; René Deenen; Hans-Jakob Steiger; Ulf D Kahlert; Jaroslaw Maciaczyk
Journal:  Oncotarget       Date:  2018-04-27

8.  IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway.

Authors:  Ku-Chung Chen; Peng-Hsu Chen; Kuo-Hao Ho; Chwen-Ming Shih; Chih-Ming Chou; Chia-Hsiung Cheng; Chin-Cheng Lee
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

Review 9.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

10.  Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningiomas.

Authors:  Maria Caffo; Emanuela Esposito; Valeria Barresi; Gerardo Caruso; Salvatore M Cardali; Mariagrazia Rinaldi; Raffaella Mallamace; Michela Campolo; Giovanna Casili; Alfredo Conti; Antonino Germanò; Salvatore Cuzzocrea; Letteria Minutoli
Journal:  Oncotarget       Date:  2017-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.